ALM Share Price Performance
€12.96
4.58 (54.65%)
6.5% undervalued intrinsic discount
€13.86
Fair Value
Price €12.96
AnalystConsensusTarget €13.86
AnalystHighTarget €16.57
Fair Value€13.86
Share Pricen/a
Almirall, S.A. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
ALM Community Narratives
AN
Fair Value €13.86 6.5% undervalued intrinsic discount
Expanding Dermatology Pipeline Will Unlock Future Treatment Horizons
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value €16.57 21.8% undervalued intrinsic discount
Rising Global Wealth And Aging Populations Will Expand Dermatology Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Expanding Dermatology Pipeline Will Unlock Future Treatment Horizons
Key Takeaways Expansion in dermatology, driven by innovative therapies and strategic partnerships, is boosting adoption rates and market share, supporting long-term revenue and margin growth. Strong cost management and favorable healthcare trends are expected to sustain elevated profitability and operational efficiency over the coming years.Read more
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
€13.86
6.5% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
10.08% p.a.
Profit Margin
10.69%
Future PE
24.35x
Price in 2028
€17.23
Rising Global Wealth And Aging Populations Will Expand Dermatology Markets
Key Takeaways Strong uptake of key drugs and expanding indications position Almirall for outsized revenue and margin growth beyond current analyst consensus. Strategic market trends, pricing power, and innovative pipeline support continued long-term outperformance and leadership in dermatological therapies.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€16.57
21.8% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
12.55% p.a.
Profit Margin
13.67%
Future PE
21.84x
Price in 2028
€20.88
Trending Discussion
Recently Updated Narratives
AN
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Fair Value: €13.86 6.5% undervalued intrinsic discount
10 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Global Wealth And Aging Populations Will Expand Dermatology Markets
Fair Value: €16.57 21.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Almirall, S.A. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 23, 2026
- 0.20
- 74.94%
- 3.88%
- 22.9%
About ALM
- Founded
- 1943
- Employees
- 2084
- CEO
- WebsiteView website
Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, nervous, and respiratory system; dermatologicals; genito urinary system and sex hormones; immunostimulants; metabolism; and systematic hormonal preparations. It has a multi-target partnership with Etherna to research and develop mRNA-based therapies for medical dermatology. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
